Press Releases

Press Releases

    Date Title View
    07/18/19
    Summary ToggleHorizon Therapeutics plc Announces U.S. FDA Acceptance of its New Drug Application to Make PROCYSBI® (Cysteamine Bitartrate) Available as Oral Granules in Packets
    PDF Version
    07/16/19
    Summary ToggleHorizon Therapeutics plc to Release Second-Quarter 2019 Financial Results and Host Webcast on Aug. 7, 2019
    PDF Version
    07/11/19
    Summary ToggleHorizon Therapeutics plc Announces Pricing of Private Offering of Senior Notes
    PDF Version
    07/10/19
    Summary ToggleHorizon Therapeutics plc Announces Proposed Private Offering of Senior Notes
    PDF Version
    07/10/19
    Summary ToggleHorizon Therapeutics plc Submits Teprotumumab Biologics License Application (BLA) for the Treatment of Active Thyroid Eye Disease (TED)
    PDF Version
    06/27/19
    Summary ToggleEyes on Graves’ Initiative Urges Action for People with Graves’ Disease and Thyroid Eye Disease
    PDF Version
    06/20/19
    Summary ToggleHorizon Therapeutics plc Initiates MIRROR Randomized Controlled Trial Evaluating KRYSTEXXA® (pegloticase injection) in Combination with Methotrexate to Increase Response Rates and Duration of Therapy
    PDF Version
    06/12/19
    Summary ToggleHorizon Therapeutics plc Highlights the Systemic Implications of Gout and the Need for Improved Patient Care Strategies with a Series of Presentations at EULAR 2019
    PDF Version
    06/04/19
    Summary ToggleHorizon Therapeutics plc to Participate in the JMP Securities Life Sciences Conference
    PDF Version
    05/29/19
    Summary ToggleHorizon Therapeutics plc and Invitae Corporation Launch Urea Cycle Disorder Genetic Testing Program
    PDF Version
    Displaying 1 - 10 of 446 results